Market Data 
Markets
Replies to post #188159 on Biotech Values
03/05/15 9:45 AM
AbbVie Inc. said late Wednesday it will buy cancer biotech Pharmacyclics Inc. in a $21 billion deal... "Doesn't make a lot sense"
04/17/15 12:21 PM
05/15/15 5:10 PM
AbbVie Inc. today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m., New York City time, on May 22, 2015.
The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on May 15, 2015, a total of approximately 42,822,941 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer.
09/14/15 9:32 AM
12/03/16 8:19 PM
In these studies (PCYC-1102 and PCYC-1103), with five years of follow-up, the ORR in patients treated with IMBRUVICA was 89%, with 14% of patients achieving complete responses (CR) [87% ORR with 29% CR in TN patients (n=31) and 89% ORR with 10% CR in r/r patients (n=101)]. Median time on study was 62 months (1-67) for TN patients and 49 months (1-67) for r/r patients.
Overall survival (OS) at five years was 92% for TN patients and 57% for r/r patients, with a PFS rate of 92% and 43%, respectively. Median OS and median duration of response (DOR) was not reached. Median PFS was not reached in TN patients and was 52 months for r/r patients.
AI
